Altimmune, Inc. (NASDAQ:ALT) Sees Insider Buying and Analyst Optimism

Director Jerome Benedict Durso's purchase of 12,500 shares indicates insider confidence in Altimmune's future.Wall Street analysts set a mean price target of $17.88 for Altimmune, suggesting a potential upside of 229.3%.The stock's current price is $4.14, with a year's trading range between $2.90 and $8.25.Altimmune, Inc. (NASDAQ:ALT) is a biopharmaceutical company focused on developing treatments for liver disease, immune modulating therapies, and vaccines. The company is gaining attention due to recent in ...